Commonwealth Scientific and Industrial Research Organisation-ko ikertzaileekin lankidetzan egindako argitalpenak (58)

2024

  1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

  2. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)

    Journal of Neuro-Oncology

2023

  1. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  2. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 2007-2019

  3. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090

  4. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69

  5. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

    British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147

  6. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet, Vol. 401, Núm. 10388, pp. 1584-1594

2022

  1. Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression

    Journal of the American Society of Nephrology : JASN, Vol. 33, Núm. 2, pp. 291-303

  2. Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))

    European journal of human genetics : EJHG

  3. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

    European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362

  4. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    New England Journal of Medicine, Vol. 386, Núm. 7, pp. 629-639

2021

  1. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials

    Journal of the American College of Cardiology, Vol. 77, Núm. 19, pp. 2366-2377

  2. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

    Stroke, Vol. 52, Núm. 5, pp. 1545-1556

  3. Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 78, Núm. 8, pp. 840-853

  4. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

    Human Genetics and Genomics Advances, Vol. 2, Núm. 3

  5. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

    Journal of Clinical Oncology, Vol. 39, Núm. 10, pp. 1108-1118

2020

  1. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

    British Journal of Cancer, Vol. 123, Núm. 5, pp. 793-802

  2. Fibromyalgia assessment screening tool: Clues to fibromyalgia on a multidimensional health assessment questionnaire for routine care

    Journal of Rheumatology, Vol. 47, Núm. 5, pp. 761-769

  3. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73